Krystal Biotech (KRYS) concentration risks

The company's disclosed concentration profile is defined by a single, high-share product dependency: its near-term prospects are described as substantially dependent on the commercial success of VYJUVEK. The character of this exposure is mixed — it combines a structural dimension (a single approved product is the primary revenue engine at this stage of the company's development) with a dependency dimension (commercial uptake, reimbursement coverage, competitive entry, and manufacturing execution can each independently affect the trajectory of that single product). There is no disclosed percentage associated with this claim, but the qualifier "substantially dependent" communicates a high-share reliance. As a single-product company, the usual portfolio diversification that mitigates product concentration risk at larger pharmaceutical firms is not present here. Pipeline progress matters, but the filing singles out VYJUVEK as the near-term anchor, meaning that any event that disrupts adoption — a competitive product launch, a payer coverage setback, a manufacturing or distribution issue, or an adverse post-market safety signal — would affect the bulk of the revenue base simultaneously. On balance, this is the dominant and only disclosed concentration: a high-share, mixed-character dependency on one commercial product. There are no geographic, customer, or supplier concentrations disclosed alongside it. Monitoring VYJUVEK's commercial trajectory — prescription trends, payer access, and manufacturing reliability — is the most direct watch item for investors evaluating this concentration profile.

For the engine’s reasoning on KRYS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.